Dimerix Ltd has released a press release.
First Paediatric Site Activated and Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- First patient enters into Open Label Extension study
- Preliminary Final Report
- Adolescent Recruitment into ACTION3 Clinical Trial
- Dimerix and Taiba enter into License Agreement for DMX-200
- Dimerix Receives PIP Approval from the UK MHRA
Later from Dimerix
- ACTION3 Trial Recruitment and Multiregion Trial Site Update
- Project PARASOL Update & Medical Advisory Board Appointment
- NEPTUNE Study Network to Enhance Phase 3 Recruitment in US
- Dimerix Receives $7.9M R&D Tax Incentive Rebate
- DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix